Home
Therapeutic Categories
- BACK
- Therapeutic Categories
- Allergy & Immunology
  - BACK
  - Allergy & Immunology
  - Chronic Spontaneous Urticaria
  - Food Allergies
  - Pediatric Food Allergies
  - Search for:
- Dermatology
  - BACK
  - Dermatology
  - Atopic Dermatitis
  - Plaque Psoriasis
  - Search for:
- Endocrinology
  - BACK
  - Endocrinology
  - Type 2 Diabetes
  - Search for:
- Gastroenterology
  - BACK
  - Gastroenterology
  - Crohn's Disease
  - Ulcerative Colitis
  - Search for:
- Hematology
  - BACK
  - Hematology
  - Chronic Immune Thrombocytopenia
  - Paroxysmal Nocturnal Hemoglobinuria
  - Sickle Cell Disease
  - Search for:
- Hepatology
  - BACK
  - Hepatology
  - Liver Fibrosis
  - Search for:
- Infectious Diseases
  - BACK
  - Infectious Diseases
  - Adolescent Vaccinations
  - COVID-19 Prevention
  - Influenza
  - Search for:
- Nephrology
  - BACK
  - Nephrology
  - IgAN
  - IgAN & C3G
  - Renal Transplant Maintenance
  - Search for:
- Neurology
- Oncology
- Ophthalmology
  - BACK
  - Ophthalmology
  - Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
  - Wet AMD
  - Search for:
- Osteoporosis
  - BACK
  - Osteoporosis
  - Osteoporosis
  - Search for:
- Psychiatry
  - BACK
  - Psychiatry
  - Major Depressive Disorder
  - Schizophrenia
  - Tardive Dyskinesia
  - Search for:
- Pulmonology
  - BACK
  - Pulmonology
  - Asthma
  - COPD
  - Interstitial Lung Disease
  - Search for:
- Rheumatology
  - BACK
  - Rheumatology
  - Psoriatic Arthritis
  - Rheumatoid Arthritis
  - Systemic Lupus Erythematosus
  - Search for:
- Urology
  - BACK
  - Urology
  - Uncomplicated Urinary Tract Infections
  - Search for:
- Search for:
Conference Reporter
Expert Directory
About Expert Perspectives
Login/Register
Search for:

clinical topic updates

Chimeric Antigen Receptor T-cell Therapy in Relapsed Mantle Cell Lymphoma

Chimeric Antigen Receptor T-cell Therapy in Relapsed Mantle Cell Lymphoma

clinical topic updates
By Caron A. Jacobson, MD, MMSc

Evaluating Combined TIM-3 Inhibition and Hypomethylating Agent Therapy in High-Risk MDS and AML

Evaluating Combined TIM-3 Inhibition and Hypomethylating Agent Therapy in High-Risk MDS and AML

clinical topic updates
By Andrew M. Brunner, MD

Hypomethylating Agent Resistance in High-Risk MDS

Hypomethylating Agent Resistance in High-Risk MDS

clinical topic updates
By Rami S. Komrokji, MD

Tuberous Sclerosis Complex: Neurologic/Neuropsychiatric Impacts, Morbidity, and Mortality

Tuberous Sclerosis Complex: Neurologic/Neuropsychiatric Impacts, Morbidity, and Mortality

clinical topic updates
By Elizabeth A. Thiele, MD, PhD

Genetic Influences on the Severity of Tuberous Sclerosis Complex

Genetic Influences on the Severity of Tuberous Sclerosis Complex

clinical topic updates
By Elizabeth A. Thiele, MD, PhD

Load More

2026 Expert Perspectives®

Privacy Policy Terms of Service About Expert Perspectives

Your California Privacy Rights Do Not Sell My Personal Information

Login Expert Perspectives

Forgot Password?

or Create an Account

Create an Account

Forgot Password?